CandlesenseCandlesense
AVBP•benzinga•

ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside

Summary

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 20, 2025 by benzinga

← Back to AVBP News
    ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside | AVBP Stock News | Candlesense